AJTMH HINARI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 71(4), 2004, pp. 400-402
Copyright © 2004 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (15)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by SINGH, N.
Right arrow Articles by DUBE, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SINGH, N.
Right arrow Articles by DUBE, A.
Related Collections
Right arrow Drug-Resistance
Right arrow Leishmaniasis

SHORT REPORT: FLUORESCENT LEISHMANIA: APPLICATION TO ANTI-LEISHMANIAL DRUG TESTING

NEELOO SINGH AND ANURADHA DUBE
Division of Biochemistry and Division of Parasitology, Central Drug Research Institute, Lucknow, India

 

ABSTRACT

Classic techniques for detecting the susceptibility of Leishmania to different drugs are time-consuming, laborious, and require the use of macrophages. The use of flow cytometry for monitoring Leishmania susceptibility to drugs is beginning to be implemented. Using green fluorescent protein (GFP), we have improved and simplified the screening procedure. We introduced a GFP marker into field strains of Leishmania causing kala-azar (visceral leishmaniasis) and explored the suitability of transgenic L. donovani promastigotes that constitutively express GFP in their cytoplasm as target cells for in vitro screening of anti-leishmanial drugs.

Received July 29, 2003. Accepted for publication November 9, 2003.

Acknowledgment: We are indebted to Stephen Beverley (Washington University, St. Louis, MO) for plasmid pXG-GFP.

Authors’ addresses: Corresponding author: Neeloo Singh, Division of Biochemistry, Central Drug Research Institute, Lucknow, India, Telephone: 91-522-212-41118, Fax: 91-522-222-3405, E-mail: neeloo888{at}yahoo.com. Anuradha Dube, Division of Parasitology, Central Drug Research Institute, Lucknow, India.




This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
N. Singh, R. Gupta, A. K. Jaiswal, S. Sundar, and A. Dube
Transgenic Leishmania donovani clinical isolates expressing green fluorescent protein constitutively for rapid and reliable ex vivo drug screening
J. Antimicrob. Chemother., August 1, 2009; 64(2): 370 - 374.
[Abstract] [Full Text] [PDF]

Home page
 J Med MicrobiolHome page
P. Misra, A. Kumar, P. Khare, S. Gupta, N. Kumar, and A. Dube
Pro-apoptotic effect of the landrace Bangla Mahoba of Piper betle on Leishmania donovani may be due to the high content of eugenol
J. Med. Microbiol., August 1, 2009; 58(8): 1058 - 1066.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
S. R. Mehta, R. Huang, M. Yang, X.-Q. Zhang, B. Kolli, K.-P. Chang, R. M. Hoffman, Y. Goto, R. Badaro, and R. T. Schooley
Real-Time In Vivo Green Fluorescent Protein Imaging of a Murine Leishmaniasis Model as a New Tool for Leishmania Vaccine and Drug Discovery
Clin. Vaccine Immunol., December 1, 2008; 15(12): 1764 - 1770.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Society of Tropical Medicine and Hygiene.